Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for LivaNova PLC (NASDAQ: LIVN), a global medical technology company headquartered in London and incorporated in England and Wales. As a foreign private issuer with securities listed in the United States, LivaNova files reports with the Securities and Exchange Commission that document material events, financial results, and corporate governance changes.
Among the filings available are Form 8‑K current reports, which LivaNova uses to announce items such as quarterly financial results, business update conference calls, and board appointments. For example, the company has filed 8‑K reports to furnish press releases on results for quarters ended June 30 and September 30, and to disclose the appointment of a new director to its Board and Audit and Compliance Committee.
Investors and analysts can also use this page to locate LivaNova’s annual and periodic reports, which typically include information on its Epilepsy and Cardiopulmonary businesses, neuromodulation therapies such as VNS Therapy, and its global operations in neurological and cardiac conditions. These documents can help readers understand segment performance, risk factors, and other disclosures that complement the company’s press releases.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, such as earnings releases or other detailed reports. Real‑time updates from the EDGAR system ensure that new LivaNova filings appear promptly, while AI highlights important sections so users can quickly see what changed, which items are being furnished rather than filed, and how corporate events may relate to LIVN stock.
Users interested in governance and oversight can review filings that describe board composition and committee membership. Those focused on financial performance can concentrate on filings that furnish earnings press releases and related metrics.
LivaNova PLC Chief Innovation Officer Ahmet Tezel reported routine equity compensation changes. Vested restricted stock units converted into 3,408 ordinary shares, with 1,186 shares withheld at $61.27 to cover taxes, leaving 4,157 ordinary shares held directly. Tezel also received 13,873 new restricted stock units and four performance stock unit awards of 4,624 units each, all subject to multi‑year vesting and performance conditions tied to revenue growth, relative total shareholder return, and adjusted earnings per share.
LivaNova PLC executive Franco Poletti, President of Cardiopulmonary, reported routine equity compensation activity involving vested restricted stock units (RSUs) settling into ordinary shares. On March 30, 2026, 3,184 ordinary shares were issued upon RSU vesting, with 1,370 shares withheld at 61.27 per share to cover tax liabilities.
After these transactions, Poletti held 10,755 ordinary shares directly, plus 219 ordinary shares held indirectly through his spouse. The RSUs vested under LivaNova’s 2015 Incentive Award Plan, 2022 Incentive Award Plan and the First Amended and Restated 2022 Incentive Award Plan, reflecting ongoing, scheduled compensation vesting rather than open‑market trading.
LivaNova PLC Chief Financial Officer Alex Shvartsburg reported multiple equity compensation events on March 30, 2026. Vested restricted stock units and performance stock units were settled in ordinary shares, and 30,835 ordinary shares were acquired through exercises. Of these, 12,868 shares were withheld at $61.27 per share to cover tax liabilities, leaving 44,647 ordinary shares held directly afterward.
Earlier performance-based grants vested above target, with awards tied to cumulative free cash flow, return on investment capital, and relative total shareholder return vesting at 122.0%, 118.71%, and 113.89% of target, respectively. New grants included 16,321 restricted stock units and several performance stock unit awards that will vest over future service and performance periods.
LivaNova PLC Chief Executive Officer Vladimir Makatsaria reported multiple equity compensation transactions. On March 30, 2026, vested restricted stock units were settled into 21,042 ordinary shares, increasing his direct holdings to 14,167 ordinary shares after shares were withheld for taxes.
The company withheld 11,159 ordinary shares at $61.27 per share to satisfy tax liabilities. Makatsaria also received new grants of 52,227 restricted stock units and three separate awards of 17,409 performance stock units each, tied to future revenue growth, relative total shareholder return, and adjusted earnings per share over performance periods through 2028.
LivaNova PLC executive Stephanie Bolton reported equity compensation activity involving restricted stock units (RSUs), performance stock units (PSUs), and ordinary shares. On March 30, 2026, she exercised vested RSUs and PSUs into ordinary shares of LivaNova PLC, consistent with the company’s incentive award plans.
These exercises delivered 17,815 ordinary shares, while 8,377 ordinary shares were withheld at $61.27 per share to satisfy tax obligations, leaving her with 22,189 ordinary shares held directly after the transactions. There were no open-market purchases or sales; the only disposition was tax withholding.
Bolton also received new equity awards on the same date, including 8,976 RSUs and several PSU grants that will vest based on future revenue growth, relative total shareholder return, and adjusted earnings per share performance through 2028–2029, subject to continued service and plan terms.
LivaNova PLC Chief Human Resources Officer Natalia Kozmina reported multiple equity compensation transactions. Vested restricted stock units were settled into 6,389 ordinary shares, with 1,374 shares withheld at $61.27 per share to cover tax liabilities.
She received new grants of 9,792 restricted stock units and three separate awards of 3,264 performance stock units each, tied to revenue growth, relative total shareholder return, and adjusted EPS performance for 2026–2028. Following these transactions, she directly holds 5,015 ordinary shares.
LivaNova PLC executive Franco Poletti, President of Cardiopulmonary, exercised 2,140 Stock Appreciation Rights that converted into the same number of ordinary shares at $57.60 per share. To cover the SAR base price and tax liabilities, 2,049 shares were withheld at $62.26 per share, leaving a net increase of 91 shares. Following these routine compensation-related transactions, Poletti holds 8,941 ordinary shares directly and 219 shares indirectly through his spouse. The F-code dispositions reflect share withholding for settlement and taxes, not open-market sales.
LivaNova PLC submitted a notice under Section 219 of the Iran Threat Reduction and Syria Human Rights Act and Section 13(r) that it made the required disclosure in its Annual Report on Form 10-K for the period ended December 31, 2025. The company states the disclosure appears in Part I, Item 1. Business of the Form 10-K.
The notice, dated February 25, 2026, is a formal attestation that the specified Iran/Syria-related disclosure was included in the filed annual report.
LivaNova PLC is a London‑based global medical technology company focused on two segments: Cardiopulmonary and Neuromodulation. It sells heart‑lung machines, oxygenators, perfusion systems, cannulae, and neuromodulation devices such as its VNS Therapy System, serving patients with drug‑resistant epilepsy, difficult‑to‑treat depression, and obstructive sleep apnea.
The company invests in R&D, including AI and software, and runs major clinical programs like the RECOVER depression study and the OSPREY trial for its aura6000 sleep apnea system. For 2025, 53% of net revenue came from the U.S., 19% from Europe, and 28% from the rest of the world. It reports extensive global regulatory, cybersecurity, trade, environmental, and compliance risks and highlights exposure to sanctions regimes through limited sales into Iran and other sanctioned markets.
As of December 31, 2025, LivaNova employed about 3,300 people in 34 countries and emphasizes culture, leadership development, and diversity initiatives as part of its human capital strategy.
LivaNova PLC reported strong fourth-quarter and full-year 2025 results while absorbing a large environmental charge and issuing 2026 guidance. Q4 revenue was $360.9 million, up 12.1% on a reported basis and 9.5% in constant currency, with double‑digit growth in both Cardiopulmonary and Neuromodulation.
For 2025, revenue reached $1.39 billion, rising 10.7% reported and 10.7% organically. GAAP diluted loss per share was $4.45 due largely to a $365.6 million SNIA environmental liability, while adjusted diluted earnings per share increased to $3.90 from $3.38.
The company guided 2026 constant-currency revenue growth between 6.0% and 7.0%, adjusted diluted earnings per share of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million. LivaNova also gained significantly higher Medicare reimbursement for VNS Therapy DRE procedures and received U.S. FDA approval for its cloud-based digital health platform, supporting future Neuromodulation growth.